Programme
The scientific programme has been developed with particular emphasis on a balanced presentation of original contributions in both basic and clinical science. The keynote lectures, symposia and workshops will be a perfect opportunity to keep up with the most recent developments in the field and lead to fruitful discussions. The invited speakers will be well known specialists who are going to share their valuable experience.
|
Last Updated: 10 June 2010 |
For the programme in full please click here (pdf)
A conference programme will be part of the conference materials for all registered participants.
Overview of programme
Physiotherapy Short Course
Airway Clearance: Tuesday June 15 (08:30-17:00) and Wednesday June 16 (08:30-12:00)
Wednesday June 16
Conference Registration / Poster Mounting
For a listing of the pre-conference programme and meetings please click here
| 13:00-14:30 | Satellite Symposium  |
| 15:00-16:30 |
Satellite Symposium |
17:00-18:00 - ECFS Annual General Meeting - ALL MEMBERS of the ECFS are invited and encouraged to attend the ECFS Annual General Meeting
18:30-21:30 - Opening Ceremony | ECFS Award | Welcome Reception
Thursday June 17
07:15-08:15 - Round Tables
| 08:30-10:00 | Symposium 1 - CF Centre Care |
| Moderators: S. Madge (UK) / C. De Boeck (BE) | |
| Running a CF Centre: What Makes the Difference? | |
| 08:30-08:45 | Children – C. De Boeck (BE) |
| 08:45-09:00 | Adults – K. Webb (UK) |
| 09:00-09:15 | What Do Patients Think? – R. Barnes (UK) |
| 09:15-09:40 | What Makes Good CF Teams Work? – M. Schechter (US) |
| 09:40-10:00 | Panel Discussion |
| 08:30-10:00 | Symposium 2 - Risk Factors in Disease Progression, Epidemiological Approach |
| Moderators: T. Wagner (DE) / C. Prados (ES) | |
| 08:30-08:52 | FEV1 Mathematical Modelling – D. VanDevanter (US) |
| 08:52-09:14 | Lung Function in the European Registry – E. Kerem (IL) |
| 09:14-09:36 | Changing Patterns of Infection– C. Goss (US) |
| 09:36-10:00 | Impact of Diabetes Mellitus – M. Ballmann (DE) |
| 08:30-10:00 | Symposium 3 - Fungal Respiratory Infections |
| Moderators: J.P. Bouchara (FR) / J. Pemán (ES) | |
| 08:30-08:52 | Epidemiology of Fungal Infection in CF – S. Husain (CA) |
| 08:52-09:14 | Identification of Fungi in CF Airways - R. Barton (UK) |
| 09:14-09:36 | ABPA – Should we Treat the Fungus? – J. Fillaux (FR) |
| 09:36-10:00 | Treatment of Fungal Infection in CF - S. Conway (UK) |
| 08:30-10:00 | Symposium 4 - From Diagnosis to Modifiers: 2010 |
| Moderators: C. Castellani (IT) / A. Munck (FR) | |
| 08:30-09:16 | What is a CF Diagnosis: US vs. European Perspective - G. Cutting (US) / M. Wilschanski (IL) |
| 09:16-09:38 | CFTR2: Genotype-Phenotype Correlation – P. Sosnay (US) |
| 09:38-10:00 | Gene Modiferes Study: an Update - M. Drumm (US) |
| 08:30-10:00 | Symposium 5 - Implementing Strategies to Improve Adherence |
| Moderators: J. Abbott (UK) / T. Havermans (BE) | |
| 08:30-08:52 | Beliefs and Adherence to Treatment - R. Horne (UK) |
| 08:52-09:14 | Barriers to Adherence in CF - A. Quittner (US) |
| 09:14-09:36 | Gender, Adherence and Clinical Outcome in Adolescents with CF - J. Patterson (US) |
| 09:36-10:00 | Behavioural Techniques for Improving Adherence in CF - R. Bernard (US) |
| 08:30-10:00 | Symposium 6 - Lessons From Models of Infection and Inflammation |
| Moderators: C. Moser (DK) / M. Cámara (UK) | |
| 08:30-08:52 | Animal Models of Inflammation - C. Moser (DK) |
| 08:52-09:14 | C. elegans as an alternative model of infection – S. Garvis (FR) |
| 09:14-09:36 | CF Pig Infection - D. Stoltz (US) |
| 09:36-10:00 | ENaC, ASL Depletion and Pulmonary Inflammation - M. Mall (DE) |
| 10:00-10:30 | Coffee Break |
| 10:30-12:00 | Symposium 7 - Grand Rounds in Pulmonary Disease |
| Moderators/ Expert panel: S. Bell (AU) / S. Conway (UK) / H. Heijerman (NL) / N. Høiby (DK) | |
| 10:30-10:43 | Acute CMV Infection in a CF Adult Complicated by Large Haemoptysis and Simultaneous Pulmonary Embolus - D.J. Dhasmana (UK) |
| 10:43-10:56 | Mycobacterium Abcessus Infection In Children With CF – K. de Winter (NL) |
| 10:56-11:09 | Scedosporium Apiospermum: A New Emerging Pathogen in Cystic Fibrosis? – M. Zanardelli (IT) |
| 11:09-11:22 | Cystic fibrosis with chronic persistent Pseudomonas aeruginosa infection complicated with Aspergillus infection? – M. Zapalka (CZ) |
| 11:22-11:35 | Eradication of Pseudomonas aeruginosa infection by use of inhaled Tobramycin in a 12 month old child - K. Jain (UK) |
| 11:35-11:48 | Abstract 461: Clinical Features of a Cystic Fibrosis Patient Chronically Colonized with Pandoraea pnomenusa Identified Using MALDI-TOF Mass Spectrometry – A. Fernandez-Olmos (ES) |
| 11:48-12:00 | Expert Panel Sum Up and Best Case Presentation Award |
| 10:30-12:00 | Symposium 8 - New Approaches to Anti-Infective Therapy in CF |
| Moderators: P. Dřevinek (CZ) / R. Cantón (ES) | |
| 10:30-10:52 | Quorum Sensing – a therapeutic target? – M. Cámara (UK) |
| 10:52-11:14 | Treating Biofilms – S. Häussler (DE) |
| 11:14-11:36 | Bacteriophage Treatment – J. Lipuma (US) |
| 11:36:12:00 | Delivery of Antimicrobials to the Site of Infection – D. Geller (US) |
| 10:30-12:00 | Symposium 9 - Nutrition in CF: Measuring, Monitoring, Prescribing |
| Moderators: L. Suárez (ES) / L. Hjelte (SE) | |
| 10:30-10:59 | Body-Image and Anthropometric Measurements - A. Morton (UK) |
| 10:59-11:28 | Monitoring and Assessing Vitamin Status – V. Stallings (US) |
| 11.28-11.52 | Probiotics and Prebiotics – Have we Reached Prime Time? - M. de Vrese (DE) |
| 11:52-12:00 | Discussion |
| 10:30-12:00 | Symposium 10 - Alternative Chloride Channels |
| Moderators: M. Gray (UK) / M. Mall (DE) | |
| 10:30-10:52 | TMEM16A – L. Galietta (IT) |
| 10:52-11:14 | Animal Models of TMEM16A - J. Rock (US) |
| 11:14-11:36 | Bestrophins in the Airways – K. Kunzelmann (DE) |
| 11:36-12:00 | CLC-2 Channels – H. De Jonge (NL) |
| 10:30-12:00 | Symposium 11 - Clinical Trials: Designs and Outcomes |
| Moderators: A. Lindblad (SE) / H. Tiddens (NL) | |
| 10:30-11:00 | Asking the Right Question - From Systematic Reviews to Patient Priotities - A. Smyth (UK) |
| 11:00-11:30 | Pitfalls of CF Trial Design - Lessons from recent CF Trials - H. Tiddens (NL) |
| 11:30-12:00 | Trial Outcomes - Lung Function in Young Children with CF - P. Aurora (UK) |
| 10:30-12:00 | Oral Poster Session 1 - Epidemiology and Screening |
| Moderators: J Telleria (ES) / K. Southern (UK) | |
| 10:30-10:40 | Abstract 37: Jejunoileal atresia and cystic fibrosis: don´t miss it! – C. Siersma (NL) |
| 10:40-10:50 | Abstract 38: Non-visualization of the Gallbladder: a Major Risk of Cystic Fibrosis when Associated with Echogenic Bowel – I. Duguépéroux (FR) |
| 10:50-11:00 | Abstract 39: A Comprehensive Genotype-Phenotype Description of 695 Cases with Fetal Bowel Anomalies – A. De Becdelièvre (FR) |
| 11:00-11:10 | Abstract 296: Transient low Fecal Elastase Levels in two CF Infants with G551D Following Newborn Screening – G. Keelty (UK) |
| 11:10-11:20 | Abstract 40: Molecular Basis of Cystic Fibrosis in Spanish Population – M.D. Ramos (SP) |
| 11:20-11:30 | Abstract 431: A Novel Method of Projecting Cystic Fibrosis Birth Cohort Survival Estimates that Overcomes Short Duration of Follow-up – A. Jackson (IE) |
| 11:30-11:40 | Abstract 423: Consanguinity and Cystic Fibrosis: the End of a Myth. Demographic Analysis of a Genealogical Database in Brittany – G. Rault (FR) |
| 11:40-11:50 | Abstract 48: Parthenogenetic Activation of Human Oocytes as a Model pf Polar Bodies PGD Feasibility for CF – V. Paracchini (IT) |
| 11:50-12:00 | Abstract 444: Building a CF Center in Gaza – a Bridge over Troubled Water – E. Kerem (IL) |
| 12:00-15:00 | Lunch |
| 12:30-14:00 | Satellite Symposium |
| 14:00-15:00 | Guided Poster Tours:
Gastrointestinal/Liver Disease/Metabolic Complications of CF/Nutrition Microbiology: CFTR/Cell Biology/Physiology |
| 14:00-15:00 | Poster Viewing - Poster authors are asked to be present next to their posters in the following categories: CFTR/Cell Biology/Physiology: Posters 49 to 72 New Therapies: Posters 73 to 92 Microbiology: Posters 93 to 170 (+ 459-460-461) Immunology/Inflammation: Posters 171 to 194 Pulmonology: 195 to 255 (+462 – 463) GI/Liver Disease/Nutrition/Metabolic Complications of CF: Posters 296 to 365 (+464) |
| 15:00-16:30 | Workshop 1 - Psychosocial - Quality of Life and Treatment Burden |
| Moderators: L. Goldbeck (DE) / M. Cebrián (ES) | |
| 15:00-15:15 | Abstract 380: Health-related Quality of Life Measurement in Cystic Fibrosis: Examining Questionnaires at an Item Level – J. Abbott (UK) |
| 15:15-15:30 | Abstract 381: Quality of Life (HRQoL) in Cystic Fibrosis: the Parents’ Perception and the Comparison with Children’s QoL – F. Alghisi (IT) |
| 15:30-15:45 | Abstract 382: Comparative Study of Three Health Related Quality of Life Instruments in Cystic Fibrosis Patients – M. Cebrián (ES) |
| 15:45-16:00 | Abstract 383: The Effect of Transmissible Pseudomonas aeruginosa Strain Infection on the Quality of Life of Adult CF Patients – A. Ashish (UK) |
| 16:00-16:15 | Abstract 394: Adherence to Nebulised Therapies does not Improve During School Holidays for Children with CF – R. Ball (UK) |
| 16:15-16:30 | Abstract 384: Health Care Preferences and Satisfaction in Adolescents with CF – G. Ullrich (DE) |
| 15:00-16:30 | Workshop 2 - Ion Transport and Pharmacology |
| Moderators: M. Valverde (ES) / F. Becq (FR) | |
| 15:00-15:10 | Overview – F. Becq (FR) |
| 15:10-15:30 | CFTR potentiators: Effect of Mutations and pH – O. Zegarra-Moran (IT) |
| 15:30-15:45 | Abstract 50: The investigational CFTR Potentiator, VX-770, Potentiated Multiple CFTR Forms in vitro – F. Van Goor (US) |
| 15:45-16:00 | Abstract 60: Identification of TRPC6 as a Novel Potential Target to Activate CaCC in Human CF Airway Epithelial Cells – J. Bertrand (FR) |
| 16:00-16:15 | Abstract 55: ΔF508-CFTR and ENaC Association – B. Berdiev (US) |
| 16:15-16:30 | Abstract 67: The Effects of Bacterial Stimulation on Prostasin Levels within the Cystic Fibrosis Lung – K. Moffitt (UK) |
| 15:00-16:30 | Workshop 3 - Bone and Liver Disease in CF |
| Moderators: I. Sermet (FR) / C. Haworth (UK) | |
| 15:00-15:10 | Overview Bone Disease – I. Sermet (FR) |
| 15:10-15:30 | Abstract 70: CFTR and Defective Human Osteoblasts: New Insights in the Osteoporotic Phenotype of Cystic Fibrosis – J. Jacquot (FR) |
| 15:30-15:50 | Abstract 340: Longitudinal Changes in Bone Mass in Children with Cystic Fibrosis: Effect of Size Adjustment Using Bone Mineral Apparent Density – J. Williams (UK) |
| 15:50-16:10 | Abstract 328: Multicentre Randomised Double Blind Placebo Controlled Trial Assessing the Effect of Weekly Risedronate on Bone Mineral Density in Adults with Cystic Fibrosis – C. Haworth (UK) |
| 16:10-16:30 | Abstract 314: Long Term Outcome of Liver Transplantation (LT) for Patients with Cystic Fibrosis Liver Disease (CFLD) – I. van Mourik (UK) |
| 15:00-16:30 | Workshop 4 - Is Epidemiology Changing? |
| Moderators: C. Castellani (IT) / M. Stern (DE) | |
| 15:00-15:20 | Impact of Screening Programmes - B. Assael (IT) |
| 15:20-15:40 | Impact of Prenatal Diagnosis on Incidence - B. Kerem (IL) |
| 15:40-15:55 | Abstract 26: 25 Years Newborn Screening Programme Suggests a Changing CF Incidence in New Zealand – M. Jaksic (NZ) |
| 15:55-16:10 | Abstract 424: Differences in Disease Severity of F508del Homozygotes across European Countries – H. Olesen (DK) |
| 16:10-16:30 | Impact of Early Pseudomonas Treatment - C. Rønne Hansen (DK) |
| 15:00-16:30 | Workshop 5 - Current Clinical Trials |
| Moderators: S. Elborn (UK) / F. Dufour (FR) | |
| 15:00-15:15 | Abstract 74: Parallel Effects of VX-770 on Transepithelial Potential Difference in Vitro and in Vivo – S. Rowe (US) |
| 15:15-15:30 | Abstract 73: Clinical Evaluation of VX-809, a Novel Investigational Oral F508del-CFTR Corrector, in Subjects with Cystic Fibrosis Homozygous for the F508del-CFTR Mutation – JP Clancy (US) |
| 15:30-15:45 | Abstract 76: Denufosol Improves Lung Function in Adolescent CF Patients – R. Moss (US) |
| 15:45-16:00 | Abstract 79: Phase III Study of Inhaled Dry Powder Mannitol (Bronchitol™) in Cystic Fibrosis – Results from the 6 and 12 Month Open Label Phase – D. Bilton (UK) |
| 16:00-16:15 | Abstract 88: Sinonasal Inhalation of Dornase Alfa Reduces Rhinosinusitis Symptoms in CF. Results of a DBPC-Cross-over Study – J. Mainz (DE) |
| 16:15-16:30 | Abstract 448: Development of Medicines for Children with CF under the New European Paediatric Regulation – I. Eichler (UK) |
| 15:00-16:30 | Oral Poster Session 2: Pulmonology and Clinical Microbiology |
| Moderators: P. Drevinek (CZ) / M. Vendrell (ES) | |
| 15:00-15:10 | Abstract 196: Microbiological Yield of Induced Sputum vs Throat Swab in CF Patients Unable to Produce Spontaneous Sputum – C. Vazquez (ES) |
| 15:10-15:20 | Abstract 195: Bronchoalveolar Lavage (BAL) Findings in Symptomatic Preschool Children with and without CF – K. De Boeck (BE) |
| 15:20-15:30 | Abstract 208: Value of Flexible Bronchoscopy and Bronchoalveolar Lavage in the Eradication of Pseudomonas Aeruginosa in Cystic Fibrosis Children – MT Romero (ES) |
| 15:30-15:40 | Abstract 116: Predictors of Progression to Chronic Pseudomonas Aeruginosa (Pa) Infection in Children with CF Classified in the Intermittent Pa Group – A. Kotwal (UK) |
| 15:40-15:50 | Abstract 102: Burkholderia and Stenotrophomonas Infections among Different European Countries – H. Olesen (DK) |
| 15:50-16:00 | Abstract 160: Macrolide Resistance of Staphylococcus Aureus Isolates Obtained from Respiratory Tract Samples of People with Cystic Fibrosis – M. Denton (UK) |
| 16:00-16:10 | Abstract 134: Role of Real Time PCR and Specific IgG in Identifying Patients with Aspergillus Colonisation – C.G. Baxter (UK) |
| 16:10-16:20 | Abstract 433: Geriatric Cystic Fibrosis: Clinical Features of Patients over 50 Years of Age – D. Hadjiliadis (US) |
| 16:20-16:30 | Abstract 434: “Old” Patients with CF: Report from Brittany (Western France) where CF is Frequent – V. Scotet (FR) |
| 16:30-17:00 | Coffee Break |
| 17:00-18:30 | Workshop 6 - Basic and Diagnostic Molecular Genetics |
| Moderators: E. Girodon (FR) / H. Cuppens (BE) | |
| 17:00-17:22 | Quality Assurance in CF Genetic Testing - E. Dequeker (BE) |
| 17:22-17:44 | Next Generation Genetic Tests: Uniform, Streamlined, Fully Quality-Assured and Automated Processing of Genetic Tests Using Next Generation Sequencing – H. Cuppens (BE) |
| 17:45-18:00 | Abstract 1: The Effect of the UPR and NMD Mechanisms on the Response to Readthrough Treatments – B. Kerem (IL) |
| 18:00-18:15 | Abstract 6: mRNA Analysis of CFTR: a Diagnostic Approach – L. Costantino (IT) |
| 18:15-18:30 | Abstract 3: Clinical and Molecular Characterization of the CF Disease Modifier Syntaxin 1A (STX1A) – T. von Känel (CH) |
| 17:00-18:30 | Workshop 7 - Pseudomonas aeruginosa: Biology and Misbehaviour |
| Moderators: H. Krogh Johansen (DK) / E. Mahenthiralingam (UK) | |
| 17:00-17:15 | Abstract 121: Post-translational Regulation of Alginate Export by an Oxygen Sensor in Pseudomonas aeruginosa – A. Schmidt (DE) |
| 17:15-17:30 | Abstract 119: Biofilm Growth Normalizes Mutation Frequencies and does not Increase Mutant Prevention Concentrations in Pseudomonas aeruginosa from Cystic Fibrosis Patients – M. García-Castillo (ES) |
| 17:30-17:45 | Abstract 112: Populations of the Pseudomonas aeruginosa Liverpool Epidemic Strain are Highly Diverse and Fluctuate in Chronically-Infected Cystic Fibrosis Patients – C. Winstanley (UK) |
| 17:45-18:00 | Abstract 98: Evaluation of the MALDI-TOF System in the Identification of Non-Fermenting Gram-Negative Rods Recovered from Sputum Samples from Cystic Fibrosis Patients – A. Fernandez-Olmos (ES) |
| 18:00-18:15 | Abstract 152: An ex vivo Sputum Model to Evaluate Antibacterial Treatments in CF Patients Chronically Colonized with Pseudomonas aeruginosa – M. Vaneechoutte (BE) |
| 18:15-18:30 | Abstract 157: Ciprofloxacin Shows Concentration-dependent Killing of Pseudomonas aeruginosa Biofilm in vitro – H. Wang (DK) |
| 17:00-18:30 | Workshop 8 - Report from the European Consensus Meeting on Allied Health Professional Research |
| Moderators: J. Bradley (UK) / S. Madge (UK) | |
| 17:00-17:22 | Addressing the barriers and needs for research - E. van der Wiel (NL) |
| 17:22-17:44 | The required skill sets and knowledge needed to undertake research - A. Gravelle (CA) |
| 17:44-18:06 | Turning a priority idea into a research question - A. Morton (UK) |
| 18:06-18:30 | Issues to consider when choosing appropriate outcome measures - J. Bradley (UK) |
| 17:00-18:30 | Workshop 9 - Advances in Antimicrobial Therapies |
| Moderators: N. Cobos (ES) / S. Bell (AU) | |
| 17:00-17:15 | Abstract 236: A Multi-Cycle Open Label Study of Nebulized Liposomal Amikacin (Arikace™) in the Treatment of Cystic Fibrosis Patients with Chronic Pseudomonas Aeruginosa Lung Infection – P. Minic (Serbia) |
| 17:15-17:30 | Abstract 159: Eradication of Methicillin-resistant Staphylococcus aureus (MRSA) in Adult Patients Attending a Regional Cystic Fibrosis Centre – D. Peckham (UK) |
| 17:30-17:45 | Abstract 81: A Double-Blind, Multinational, Randomized, Placebo-Controlled Trial Evaluating Aztreonam for Inhalation Solution (AZLI) in Patients with Cystic Fibrosis (CF), Mild Lung Disease and P. aeruginosa (PA) – C. Wainwright (AU) |
| 17:45-18:00 | Abstract 82: Safety and Efficacy of Tobramycin Inhalation Powder (TIP) in Treating CF Patients Infected with Pseudomonas aeruginosa (Pa) – M. Konstan (US) |
| 18:00-18:15 | Abstract 86: Effects of Inhaled MP-376 (Aeroquin, Levofloxacin Inhalation Solution) on Lung Function in Stable Cystic Fibrosis (CF) Patients with Chronic pseudomonas aeruginosa (PA) Lung Infection – P. Flume (US) |
| 18:15-18:30 | Abstract 209: Comparative Efficacy and Safety of Four Randomized Regimens to Treat Early Pseudomonas aeruginosa Infection in Children with Cystic Fibrosis – F. Accurso (US) |
| 17:00-18:30 | Workshop 10 - Sexuality and Sexual Health |
| Moderators: K. Colpaert (BE) / V. Hall (UK) | |
| 17:00-17:20 | Abstract 397: The Prevalence of ‘Risky Behaviour’ in Adults with Cystic Fibrosis – N. Simmonds (UK) |
| 17:20-17:40 | Abstract 398: An Audit of Sexual Health Awareness in Adult Cystic Fibrosis Patients – C. Broughton (UK) |
| 17:40-18:00 | Abstract 399: Prevalence of Erectile Dysfunction in Cystic Fibrosis – D. Wat (UK) |
| 18:00-18:20 | Abstract 400: Fatherhood in Males with Cystic Fibrosis: Modality of Conception and Impact on Clinical Status – S. Conway (UK) |
| 18:20-18:30 | Discussion and Wrap Up |
| 17:00-18:30 | Oral Poster Session 3 - Nutrition and Metabolic Complications |
| Moderators: L. Hjelte (SE) / A. Matson (AU) | |
| 17:00-17:10 | Abstract 319: Prognostic Relevance of Hypoglycemia Following an Oral Glucose Challenge in Cystic Fibrosis – K. Radike (DE) |
| 17:10-17:20 | Abstract 322: A High Prevalence of Cardiac Autonomic Dysfunction in CF Patients with and without CF-Related Diabetes (CFRD) – R. Rashid (UK) |
| 17:20-17:30 | Abstract 317: Use of Continual Glucose Monitoring to Assess Real Life Glycaemia in Adults with CF – J. Helm (UK) |
| 17:30-17:40 | Abstract 321: Insulin Secretion, Lung Function and Nutritional Status in Normal Glucose Tolerance Cystic Fibrosis Patients – G. Alicandro (IT) |
| 17:40-17:50 | Abstract 297: Reproducibility of Coefficient of Fat Absorption (CFA) in Cystic Fibrosis Patients with Pancreatic Insufficiency – D. Borowitz (US) |
| 17:50-18:00 | Abstract 339: Body Composition and Lung Function in Young Children with Cystic Fibrosis – J. Williams (UK) |
| 18:00-18:10 | Abstract 357: Predictors of Vitamin K Status in Children and Young Adults with Cystic Fibrosis – V. Stallings (US) |
| 18:10-18:20 | Abstract 301: Increased Duodeno-gastroesophageal Reflux in CF Adults – A. Pauwels (BE) |
| 18:20-18:30 | Abstract 310: Liver Elastography to Detect Early Stage Cystic Fibrosis Related Liver Disease in Children – C. Van der Feen (NL) |
| 19:00-20:30 | Satellite Symposium |
Friday June 18
07:15-08:15 - Round Tables
07:30-08:30 - Journal of Cystic Fibrosis Editorial Board Meeting
| 08:30-10:00 | Symposium 12 - Paradigm Shift in Treatment |
| Moderators: A. Smyth (UK) / tbc | |
| 08:30-08:52 | BAL Directed Therapy – C. Wainright (AU) |
| 08:52-09:14 | Improving Mucociliary Clearance – F. Ratjen (CA) |
| 09:14-09:36 | New Inhaled Antibiotic Treatments – More of the Same? – A. Bush (UK) |
| 09:36-10:00 | Mutation Specific Treatment - I. Sermet (FR) |
| 08:30-10:00 | Symposium 13 - Functional Genomics and Proteomics |
| Moderators: M. Drumm (US) / A. Edelman (FR) | |
| 08:30-08:52 | Functional Genomics: How Far is it From Clinical Application? – M. Drumm (US) |
| 08:52-09:14 | Functional Genomics: Making an Impact on CF – M.D. Amaral (PT) |
| 09:14-09:36 | Silencers and Enhancer-Blockers in the Greater CFTR Locus – L. Elnitski (US) |
| 09:36-10:00 | Global Proteomic Approach – A. Edelman (FR) |
| 08:30-10:00 | Symposium 14 - Pro/Con Debates: |
| Moderators: M. Griese (DE) / J. Govan (UK) | |
| Molecular Diagnostics Should be Routine in CF Microbiology | |
| 08:30-08:47 | Pro: R. Cantón (ES) |
| 08:47-09:04 | Con: N. Høiby (DK) |
| 09:04-09:15 | Discussion |
| Lung Function Measurements are no longer a credible endpoint for Clinical Trials in CF | |
| 09:15-09:32 | Pro: M. Ballmann (DE) |
| 09:32-09:49 | Con: A. Innes (UK) |
| 09:49-10:00 | Discussion |
| 08:30-10:00 | Symposium 15 - Physiotherapy State of the Art |
| Moderators: I. Maguire (IE) / A. Rios (ES) | |
| 08:30-08:52 | Inhalations: Devices, Medications, Body Position and Breathing Pattern – M. Elkins (AU) |
| 08:52-09:14 | Musculo-Skeletal Issues - G. Morgan (UK) |
| 09:14-09:36 | Exercise – H. Hebestreit (DE) |
| 09:36-10:00 | Airway Clearance – M. McIlwaine (CA) |
| 08:30-10:00 | Symposium 16 - Liver Disease in CF |
| Moderators: M. Wilschanski (IL) / K. Gaskin (AU) | |
| 08:30-08:52 | Animal Models of CF Liver Disease – S. Freedman (US) |
| 08:52-09:14 | How the Discovery of Modifier Genes Changes our Approach to Diagnosis and Management of CF Liver Disease – P. Durie (CA) |
| 09:14-09:36 | Management of Severe Liver Disease – M. Cipolli (IT) |
| 09:36-10:00 | Long Term UDCA Treatment in Liver Disease – A. Lindblad (SE) |
| 08:30-10:00 | Dissemination of the The International Depression and Anxiety Epidemiological Study (TIDES) |
| 08:30-08:45 | Introduction to TIDES - M. Schechter (US) |
| 08:45-08:57 | Abstract 366: The International Depression and Anxiety Epidemiological Study (TIDES): Preliminary Results from the United States- A. Quittner (US) |
| 08:57-09:09 | Abstract 367: The International Depression and Anxiety Epidemiological Study (TIDES): Results from Germany - L. Goldbeck (DE) |
| 09:09-09:21 | Abstract 368: The International Depression and Anxiety Epidemiological Study (TIDES): Results from Italy - P. Catastini (IT) |
| 09:21-09:33 | Abstract 369: The International Depression and Anxiety Epidemiological Study (TIDES): Preliminary Results from Turkey - H. Yuksel (TR) |
| 09:33-09:45 | Abstract 370: The International Depression and Anxiety Epidemiological Study (TIDES): UK Study - C. Cowperthwaite (UK) |
| 09:45-10:00 | International Comparisons - A. Quittner (US) |
| 10:00-10:30 | Coffee Break |
| 10:30-12:00 | Symposium 17 - How can Registries be used to Improve Quality of Care? |
| Moderators: M. Stern (DE) / C. Vázquez (ES) | |
| 10:30-10:52 | Impact of Newborn Screening on Quality of Care – S. Ravilly (FR) |
| 10:52-11:14 | Role of Peer Reviewed Site Visits – D. Bilton (UK) |
| 11:14-11:36 | Therapy Policy Evaluation – A. Lindblad (SE) |
| 11:36-12:00 | From Registry to Quality Management – M. Stern (DE) |
| 10:30-12:00 | Symposium 18 - CFTR 2010 |
| Moderators: D. Sheppard (UK) / O. Zegarra-Moran (IT) | |
| 10:30-10:52 | Endocytic Cycling of CFTR and F508 Del-CFTR – M. Gentzsch (US) |
| 10:52-11:14 | Folding Abnormalities and their Correction in F508 Del-CFTR – B. Kleizen (NL) |
| 11:14-11:36 | CFTR in Airway Smooth Muscle – F. Becq (FR) |
| 11:36-12:00 | Lessons from Tissue-specific CFTR Null Mice – M. Drumm (US) |
| 10:30-12:00 | Symposium 19 - Chest Imaging |
| Moderators: H. Tiddens (NL) / S. Gartner (ES) | |
| 10:30-10:52 | Chest Radiograph in Determining Severity of Lung Disease – P. Farrell (US) |
| 10:52-11:14 | CT in Pulmonary Infection - A. Brody (US) |
| 11:14-11:36 | MRI: Clinical Applications or Too Early? – M. Puderbach (DE) |
| 11:36-12:00 | Imaging Mucus Clearance – J. Davies (UK) |
| 10:30-12:00 | Symposium 20 - New Challenges in CF Infection |
| Moderators: M. Denton (UK) / F. Baquero (ES) | |
| 10:30-10:52 | Respiratory Viruses – K. Van der Ent (NL) |
| 10:52-11:14 | Treating Anaerobes in CF – Should we and what with? – M. Tunney (UK) |
| 11:14-11:36 | Sinus Infections – H. Krogh Johansen (DK) |
| 11:36-12:00 | Antibiotic Allergy – D. Naisbitt (UK) |
| 10:30-12:00 | Symposium 21 - CFRD - New challenges for the Young Adult with a Second Diagnosis |
| Moderators: V. Hall (UK) / K. Colpaert (BE) | |
| 10:30-10:52 | Developing Collaborative Clinics – D. Hardin (US) |
| 10:52-11:14 | The Role of the CF Diabetes Nurse Specialist – K. Marwa (UK) |
| 11:14-11:36 | Living with a Second Diagnosis – A. Gravelle (CA) |
| 11:36-12:00 | Adolescents with CFRD – Transition Between the Services – E.J. Hunstad (NO) |
| 12:00-15:00 | Lunch |
| 12:30-14:00 | Satellite Symposium |
| 14:00-15:00 |
Guided Poster Tours: Nursing and Psychosocial Issues Physiotherapy |
| 14:00-15:00 |
Poster Viewing - Poster authors are asked to be present next to their posters in the following categories: |
| 15:00-16:30 | Workshop 11 - Pulmonology Exacerbations |
| Moderators: M. Griese (DE) / H. Heijerman (NL) | |
| 15:00-15:22 | Monitoring exacerbations – H. Heijerman (NL) |
| 15:22-15:39 | Abstract 197: Detection of Viruses in Pulmonary Exacerbations in CF – A. Malfroot (BE) |
| 15:39-15:56 | Abstract 141: Pulmonary Exacerbations in Adult Patients with Cystic Fibrosis Associated with Positive Viral PCR – D. Peckham (UK) |
| 15:56-16:13 | Abstract 216: Clinical Features and Outcomes of Cystic Fibrosis Pulmonary Exacerbations Presenting with Normal Inflammatory Markers – M. Ibrahim (UK) |
| 16:13-16:30 | Abstract 425: Incidence and Risk Factors for Frequent Pulmonary Exacerbation in Cystic Fibrosis – M. Parkins (CA) |
| 15:00-16:30 | Workshop 12 - GI Case Presentations |
| Moderators: Expert Panel | |
| Case Presentations | |
| 15:00-16:30 | Workshop 13 - CFTR and Cell Biology |
| Moderators: B. Kleizen (NL) / M. Gentzsch (US) | |
| 15:00-15:18 | Overview - M. Gentzsch (US) |
| 15:18-15:36 | Abstract 54: Pharmacological Stabilization of ΔF508-CFTR at the Cell Surface: Design of CAL-Selective PDZ Inhibitors – P. Cushing (US) |
| 15:36-15:54 | Abstract 52: CFTR Missing the Last Four Transmembrane Segments and Nucleotide Binding Domain 2 Resides in the ER but Escapes the Cell’s Quality Control Mechanism – L. Cebotaru (US) |
| 15:54-16:12 | Abstract 65: Characterization of the Human Bronchiolar Epithelium Regeneration – C. Coraux (FR) |
| 16:12-16:30 | Abstract 66: The Mechanism of PAR-2 Mediated Mucus Secretion in Airway Submucosal Gland – H.-J. Lee (Korea) |
| 15:00-16:30 | Workshop 14 - Understanding Airway Inflammation |
| Moderators: C. Taggart (UK) / A. Edelman (FR) | |
| 15:00-15:06 | Introduction and Overview – C. Taggart (UK) |
| 15:06-15:20 | Abstract 171: Trypsin and Neutrophil Elastase Regulate CFTR Expression and Function in Cystic Fibrosis – JM Sallenave (FR) |
| 15:20-15:34 | Abstract 172: A Role for Cathepsin S in the Pathogenesis of Cystic Fibrosis Lung Disease – S. Weldon (UK) |
| 15:34-15:48 | Abstract 173: Genetic and Pharmacological Evidence for Critical Role of Macrophage Elastase in Emphysema Formation in βENaC-Overexpressing Mice – S. Diemer (DE) |
| 15:48-16:02 | Abstract 174: Flagellin/TLR5-dependent Modulation of Alveolar Macrophage & Epithelial Cell Activity by the Antimicrobial Molecule Trappin-2 – JM. Sallenave (FR) |
| 16:02-16:16 | Abstract 175: Histone Deacetylases (HDACs) and IFRD1 in CF Airway Epithelial Cell Models – E. Blanchard (FR) |
| 16:16-16:30 | Abstract 176: Altered Expression of T-Cell Immunoglobulin and Mucin-Domain-Containing Molecule-1 (TIM-1) and TIM-3 in the Cystic Fibrosis Airway – I. Vega-Carrascal (IE) |
| 15:00-16:30 | Workshop 15 - What's New in Physiotherapy? |
| Moderators: A. Valiente (ES) / S. Van Laethem (BE) | |
| 15:00-15:15 | Abstract 256: Patients with Cystic Fibrosis can Preserve Peak Working Capacity, even if Lung Function is Substantially Impaired – L. Lannefors (SE) |
| 15:15-15:30 | Abstract 273: CF and Sport- Encouraging the Motivation by a Specific Sport Program – S. Junge (DE) |
| 15:30-15:45 | Abstract 267: Differences in Quality of Life, Lung Function and Hospitalisation Rates for Adults with Cystic Fibrosis, according to Exercise Participation – T. Dwyer (AU) |
| 15:45-16:00 | Abstract 281: Randomised Controlled Two-centre Trial of Non-invasive Ventilation (NIV)-assisted Chest Physiotherapy (CPT) during an Acute Exacerbation of Cystic Fibrosis – T. Dwyer (AU) |
| 16:00-16:15 | Abstract 263: Breathlessness during Exercise in Cystic Fibrosis – C. Reilly (UK) |
| 16:15-16:30 | Abstract 286: Does Body Position during Inhalation of a Nebulised Aerosol Influence the Pattern of Deposition in Adults with and without Cystic Fibrosis (CF)? – R. Dentice (AU) |
| 16:30-17:00 | Coffee Break |
| 17:00-18:30 | Workshop 16 - Late Breaking Science |
| Moderators: M. Hug (DE) / M. D. Amaral (PT) | |
| Abstracts to be inserted | |
| 17:00-18:30 | Workshop 17 - Monitoring CF Lung Disease |
| Moderators: F. Ratjen (CA) / R. Kraemer (CH) | |
| 17:00-17:15 | Abstract 217: Monitoring of Young Children with CF – E. Bakker (NL) |
| 17:15-17:30 | Abstract 218: Ventilation Inhomogeneity Correlates with Airway Colonization in Patients with CF – K. Green (DK) |
| 17:30-17:45 | Abstract 219: Lung Clearance Index: Wash-in Data Compared to Wash-out Data – M. Proesmans (BE) |
| 17:45-18:00 | Abstract 220: Transition of Lung Function from Infants to Children with Cystic Fibrosis (CF), Evaluated by Whole-body Plethysmography – R. Kraemer (CH) |
| 18:00-18:15 | Abstract 221: Validation of the Liverpool Respiratory Symptom Questionnaire (LRSQ) in Well Children with Cystic Fibrosis (CF) – R. Trinick (UK) |
| 18:15-18:30 | Abstract 426: The Sensitivity of Lung Disease Surrogates in Children with CF: Limited Value of FEV1 – D. Sanders (US) |
| 17:00-18:30 | Workshop 18 - Screening and Diagnosis of CF |
| Moderators: M. Macek (CZ) / M. Tzetis (GR) | |
| 17:00-17:18 | Report of the ECFS/EuroCareCF Working Group on CFTR-RD – C. Férec (FR) |
| 17:18-17:36 | Newborn Screening in Catalonia: 10 years of Experience – S. Gartner (ES) |
| 17:36-17:54 | Abstract 34: A Novel Paradigm for Attributing the Diagnosis of CF Disease – C. Ooi (CA) |
| 17:54-18:12 | Abstract 25: Sweat Chloride (SC) Concentration and CFTR Mutation Class among Infants Identified by Newborn Screening (NBS) in California (CA) – J. Zirbes (US) |
| 18:12 -18:30 | Abstract 22: Retrospective Analysis of Stored Dried Blood Spots (Guthrie Cards) Using IRT Measurements to Detect Clinically Diagnosed Children with Cystic Fibrosis in Switzerland – J. Barben (CH) |
| 17:00-18:30 | Workshop 19 - Microbiology/Antibiotics - Typing and Virulence |
| Moderators: J. Lipuma (US) / N. Høiby (DK) | |
| 17:00-17:15 | Abstract 113: Multilocus Sequence Typing (MLST) of Pseudomonas aeruginosa Collected from Different Ecological Niches – T. Kidd (AU) |
| 17:15-17:30 | Abstract 122: Molecular Analysis of Staphylococcus Aureus Isolates from an Ongoing Prospective Observational Longitudinal Multicenter Study – B. Kahl (DE) |
| 17:30-17:45 | Abstract 103: The Role of PCR in Early Diagnosis and Monitoring of Infection with Burkholderia cepacia complex – P. Drevinek (CZ) |
| 17:45-18:00 | Abstract 99: Contribution Of Mobile Genetic Elements to the Competitiveness of a Cystic Fibrosis Epidemic Strain – J. Fothergill (UK) |
| 18:00-18:15 | Abstract 118: Modes of Interaction between Pseudomonas aeruginosa and Obligate Anaerobes – D. Worlitzsch (DE) |
| 18:15-18:30 | Abstract 115: Origin of Ps.aeruginosa Strains Causing Chronic Colonisation in CF Patients – C. Williams (UK) |
| 17:00-18:30 | Workshop 20 - Nursing/Psychosocial - Complex Case Presentations |
| Moderators: K. Colpaert (BE) / T. Havermans (BE) | |
| 17:00-17:21 | Psychological impact of lung transplantation for children with cystic fibrosis, two case studies – E. Hoey-Eikelhof (NL) |
| 17:21-17:42 | More than poor compliance - where to go next ? – J. Maddison (UK) |
| 17:42-18:03 | Concerns for the future in a transfer from the children's hospital to the adult clinic of a 17 year old young female with CF in a terminal stage – I. Heeres (NL) |
| 18:03-18:24 | When (serious) behavioural problems interfere with good medical care: a challenge for residential care - L. Govaerts (BE) |
| 18:24-18:30 | Best case presentation award |
| 17:00-18:31 | Oral Poster Session 4: Physiotherapy Case Presentations |
| Moderators: B. Button (AU) / F. Van Ginderdeuren (BE) | |
| 17:00-17:13 | My Cystic Fibrosis (CF) Doesn't Cause Me Any Problems... A Cautionary Tale Post Surgical Intervention - H. Jay (UK) |
| 17:13-17:26 | Use of the "Start-up Exercise Programme" to Improve Health-related Objective Measures and Overcome Psychological Barriers to Exercise in Cystic Fibrosis - S. Cameron (UK) |
| 17:26-17:39 | Exercising Embolisations - L. McCorry (UK) |
| 17:39-17:52 | Headaches in Chronic Respiratory Failure: Are We Missing Something? - A. Rochester (UK) |
| 17:52-18:05 | Team Work to Change Destructive Thoughts about Having CF and to Adhere to Treatment - M. Sahlberg (SE) / C. Boberg (SE) |
| 18:05-18:18 | Chronic Cough in an Adult Patient with Cystic Fibrosis - M. Ortfelt (SE) |
| 18:18-18:31 | Positive Pressure Insufflation Used to Re-expand Lung Following Collapse from ABPA - J. Johnstone (UK) |
| 19:00-20:30 | Satellite Symposium |
| 21:00 | Conference Dinner & Party |
Saturday June 19
| 09:00-10:30 | Symposium 22 - Pancreas, Pancreatic Enzyme Therapy, Pancreatitis |
| Moderators: C. Taylor ( UK ) / M. Cipolli (IT) | |
| 09:00-09:22 | New, Improved and Approved Pancreatic Enzyme Preparations – D. Borowitz (US) |
| 09:22-09:44 | What do we Need in the Ideal Pancreatic Enzyme: the Role of Phospholipases – K. Gaskin (AU) |
| 09:44-10:06 | Practical Enzyme Use in Difficult Clinical Situations – D. Kalnins (CA) |
| 10:06:10:30 | Risk of Pancreatitis and Mild CFTR Mutations – K. Ooi (CA) |
| 09:00-10:30 | Symposium 23 - Lung Transplantation |
| Moderators: A. Fisher (UK) / A. Román (ES) | |
| 09:00-09:22 | Indications for Referral. When and Where to Talk with the Patient - A. Fisher (UK) |
| 09:22-09:44 | Transplantation in Children – P. Aurora (UK) |
| 09:44-10:06 | Post Transplantation Complications - A. Solé (ES) |
| 10:06:10:30 | Post Transplant Management and What the CF Centre Needs to Know and Do – D. Hadjiliadis (US) |
| 09:00-10:30 | Symposium 24 - Vitamins, Oxidants |
| Moderators: S. Elborn (UK) / G. Döring (DE) | |
| 09:00-09:22 | Vitamin D and Inflammation – P. McCray (US) |
| 09:22-09:44 | Neutrophil Biology in the CF Airway – D. Hartl (DE) |
| 09:44-10:06 | Oxidants in the Inflammatory Process – Sources and Inducers – P.Ø. Jensen (DK) |
| 10:06-10:30 | Novel Anti-Inflammatory Therapies – G. Döring (DE) |
| 09:00-10:30 | Symposium 25 - Current Issues in CF Genetics |
| Moderators: T. Casals (ES) / B. Kerem (IL) | |
| 09:00-09:22 | Regulation of CFTR Gene Expression – A. Harris (US) |
| 09:22-09:44 | Impact of CFTR Mutations on Splicing – P. Fanen (FR) |
| 09:44-10:06 | PGD: an Overview – A. Girardet (FR) |
| 10:06-10:30 | Spain and Latin America connection: genetics overview – T. Casals (ES) |
| 09:00-10:30 | Symposium 26 - Living with CF across the lifespan |
| Moderators: V. Bregnballe (DK) / M. Kirszenbaum (FR) | |
| 09:00-09:22 | QOL Across the Age Span – L. Goldbeck (DE) |
| 09:22-09:44 | Adolescent Issues – T. Havermans (BE) |
| 09:44-10:06 | Adult Survey of Health and Social Experiences – S. Madge (UK) |
| 10:06-10:30 | Report on the Aging Study – N. Simmonds (UK) |
| 10:30-11:00 | Coffee Break |
| 11:00-12:30 | Plenary - Treating Cystic Fibrosis |
| Moderators: S. Elborn (UK) / C. Castellani (IT) | |
| 11:00-11:30 | Restoring CFTR Function in CF Airways - R. Boucher (US) |
| 11:30-12:00 | Current Treatments for CF to Prevent Disease Progression - S. Stick (AU) |
| 12:00-12:30 | ECFS President's Address; ECFS Projects - S. Elborn (UK) |
| 12:30-13:00 | Closing Ceremony (will include the awards for the Best Posters) |
| 13:30-18:00 | Scientific Committee Meeting - Hamburg 2011 |
The conference organisers reserve the right to modify the programme
Printer-friendly version